CORPORATE OVERVIEW2020

TOKYOTakeda Global HQ

GREATERBOSTONAREAGlobal Hub

GLOBAL REVENUE

A Global, Values-based, R&D-driven Biopharmaceutical Leader

3RESEARCHSITES

36MANUFACTURING SITES

30+TOP EMPLOYER® IN

COUNTRIES& REGIONSA S O F F E B R U A R Y 2 0 2 0

13.9%EMERGING

MARKETS APPROX.

30BN USD

19.6%EUROPE &

CANADA 18.0%JAPAN

48.5%U.S.

EMPLOYEES

20%EMERGING

MARKETS

31%EUROPE &

CANADA13%JAPAN

36%U.S.

2

APPROX.

50,000EMPLOYEES

80PRESENCE: APPROX. IN

COUNTRIESA S O F F E B R U A R Y 2 0 2 0 4.5

R&D INVESTMENT APPROX.

BN USD PER YEARAs of December 31, 2019

A S O F D E C E M B E R 2 0 1 9

A S O F M A R C H 2 0 2 0

01HERITAGE

02DIVERSITY

03INNOVATION

HOW CAN WEDO MORE FOROUR PATIENTS?

04SUSTAINABILITY

01HERITAGE

Takeda was founded in Doshomachi, Osaka, which became the heart of the Japanese medicine industry during the Edo period. Many pharmaceutical companies continue to have their headquarters in this area, leading it to be known as the “medicine town.”

“Work with integrity and deal with medicine as though the patients

being treated were your own children”

We serve the needs of our patients, wherever they are. We earn the trust of society and customers through Takeda-ism. We are recognized as best in class because of agility and innovation, qualities that help us build a steady pipeline and deliver growth, year on year.

Corporate Philosophy

Our Mission is to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine.

We take action and make decisions by focusing on our four priorities, in order of:

5

OUR PRIORITIES

VALUES TAKEDA-ISM

1Putting the patient at the center

2Building trust with society

3Reinforcing our reputation

4Developing the business

Since our founding in 1781, our integrity-centered values have guided us in everything we do. They have been inherited as Takeda-ism, with patients as our priority. Takeda-ism continues to guide us in our pursuit of better health for people worldwide.

VISION

MISSION

FOR

SO

CIE

TY

FOR

BU

SIN

ES

S

Our History 1781 - 1979

1781COMPANY FOUNDEDChobei Takeda I sets up his business in Osaka

1915OSAKA FACTORYOpens as “Takeda Pharmaceutical Manufacturing Plant”

1895PRODUCTIONPharmaceutical manufacturing begins in Takeda’s factory

1871INTERNATIONAL TRADETakeda pioneers in the importation of western medicines

1914PROPRIETARY RESEARCHactivities begin

1943COMPANY NAMEbecomes "Takeda Pharmaceutical Company Limited"

1949INITIAL PUBLIC OFFERING Takeda listed on the stock market

1951INTERNATIONAL BUSINESSStarts with North and Central America and Asia

1940“NORI” PRINCIPLESwhich underpin Takeda-ism, are established

1950sPANVITAN® & ALINAMIN® Japan’s first multivitamin product and a Vitamin B1 derivative launch

1961COMPANY LOGOThe current “Dakiyama” logois created

1963TAKEDA SCIENCE FOUNDATIONis established to encourage promising research and science technology

1960SHOSHISHA FOUNDATIONis established to support talented students who will contribute to society

1933TAKEDA GARDENFor Medicinal Plant Conservation opens

6

1946HIKARI FACTORYOpens in Yamaguchi prefecture

FOR

SO

CIE

TY

FOR

BU

SIN

ES

S

Our History 1980 - Present

1980s & 90sEXPANSION OF INTERNATIONAL BUSINESSaccelerates with the launch of leuprorelin, lansoprazole, candesartan, pioglitazone

2011NYCOMED AQUISITIONexpands Takeda’s global footprint into more than 70 countries worldwide

2019TAKEDA INITIATIVE 2 launched to improve maternal and child health by integrating quality HIV, TB, and malaria services in Africa

2009Takeda joins the UNITED NATIONS GLOBAL COMPACT

2008MILLENNIUM PHARMACEUTICALSacquisition enhances innovation in oncology

2019SHIRE ACQUISITIONmakes Takeda a global biopharmaceuWcal leader with a presence in approximately 80 countries

2010TAKEDA INITIATIVEis formed to support the development of healthcare professionals in Africa

2016ACCESS TO MEDICINESprogram launched to improve access to care and treatment for patients in underserved communities

GLOBAL CSR PROGRAM launched to contribute to the better health of people through disease prevention.

2018NEW YORK STOCK EXCHANGE LISTINGThe only pharmaceutical company listed on both the TSE and the NYSE

SHONAN HEALTH INNOVATION PARKopens as the first pharma-led open innovation ecosystem in Japan

TAKEDA GLOBAL HEADQUARTERS opens in Tokyo, providing an environment that supports diverse workstyles

7

02DIVERSITY

Diverse perspectives lead to insightful solutions

Our employees are the cornerstone of our success. Diverse workplaces where all employees are welcomed and empowered inspire them and enable health innovation that meets the needs of patients, customers and communities.

Takeda ExecuKve Team (TET)SW

ITZE

RLA

ND

SINGAPO

RE

R ICA R DO MA R EKPresident, Growth & Emerging Markets Business Unit

GILES PLA T FO R DPresident, Europe & Canada Business Unit

T HO MA S WO ZNIEWSKIGlobal Manufacturing & Supply Officer

J ULIE KIM President, Plasma-Derived Therapies Business Unit

MWA NA LUG O G OChief Ethics & Compliance Officer

U.S.

A NDY PLUMPPresident, Research & Development

R A MO NA SEQUEIR A President, U.S. Business Unit and Global Portfolio Commercialization

T ER ESA BIT ET T IPresident, Global Oncology Business Unit

R A J EEV V ENKA YYAPresident, GlobalVaccine Business Unit

GER A R D ( JER R Y) GR ECOGlobal Quality Officer

MA R CELLO A G O ST IGlobal Business Development Officer

JAPA

N

CHR ISTO PHE WEBERPresident & CEO

MA SA T O IWA SA KIPresident, Japan Pharma Business Unit

CO ST A SA R O UKO SChief Financial Officer

YO SHIHIR O NA KA GA WAGlobal General Counsel

MILA NO FUR UT ACorporate Strategy Officer & Chief of Staff

PA DMAT HIR UV ENG A DA MChief Human Resources Officer

T A KA KO O HYA BUChief Global Corporate Affairs Officer

9

The gender, age and geographic diversity of the Takeda ExecuPve Team together with its funcPonal experPse and unparalleled experience, ensures quick and transparent decision-making

Board of Directors

SHIR O KUNIYAIndependent Director

KO J I HA T SUKA WAIndependent Director,Chair of A&SC

MA SA HIR O SA KA NEIndependent DirectorChair of the Board meetingChair of Nomination Committee

CB

NC

COMPENSATION COMMITTEE

NOMINATION COMMITTEE2

INDEPENDENT DIRECTOR

CHAIR OF THE BOARD MEETING

NC

CB

CC

YO SHIA KI FUJ IMO R IIndependent Director

CC

INDEPENDENT DIRECTORS1

IA N CLA R KIndependent Director

CC

EMIKO HIG A SHIIndependent DirectorA&SC memberChair of Compensation Committee

CC

ST EV EN G ILL ISIndependent Director

NC

T O SHIYUKI SHIG AIndependent Director

NC

O LIV IER BO HUO NIndependent Director

CC

J EA N-LUC BUT ELIndependent Director

NC

MICHEL O R SING ERIndependent DirectorA&SC Member

NC

AUDIT & SUPERVISORY COMMITTEE (A&SC)

CHR ISTO PHE WEBERRepresentaBve Director,President & CEO

A NDR EW PLUMPDirector, President, Research & Development

YA SUHIKO YA MA NA KADirector,A&SC member

MA SA T O IWA SA KIDirector, President, Japan Pharma Business Unit

INTERNAL DIRECTORS

CO ST A SA R O UKO SDirector,Chief Financial Officer

101. As def ined by Tokyo Stock Exchange l isting rules2. Christophe Weber participates in the committee as an observer

Takeda cherishes best-in-class governance. Takeda’s board is comprised of 16 experienced global leaders from diverse backgrounds. Eleven of them are independent external directors.

Corporate Governance Diagram

11

Our advanced and robust corporate governance model has been and will continue to be, critical to our success.

T A KEDA EX ECUT IV E T EA M (T ET )

R E P O R T I N G

C O N S U L T A T I O N

RECOMMENDATION

A P P O I N T M E N T/D I S M I S S A L /N O N - R E A P P O I N T M E N TO F M E M B E R S

NO MINA T IO N CO MMIT T EE

CO MPENSA T IO N CO MMIT T EE

A CCO UNT ING A UDIT O RA UDIT A ND SUPER V ISO R Y CO MMIT T EE

T HE G R O UP INT ER NA L A UDIT DEPA R T MENT

A U D I T I N G

R E P O R T I N G I N S T R U C T I O N

R E P O R T I N G / S T A T E M E N TO F O P I N I O N

A P P O I N T M E N T / D I S M I S S A LO F M E M B E R S

R E P O R T I N GR E P O R T I N G

HEA D O F EA CH UNIT A ND PR ESIDENT S O F T HE G R O UP CO MPA NIES

R E P O R T I N G

D I S C U S S I O N /R E P O R T I N G

S U P E R V I S I O N

PR ESIDENT A ND CHIEF EX ECUT IV E O FFICE (CEO )

PO R T FO LIO R EV IEW CO MMIT T EE

BUSINESS R EV IEW CO MMIT T EE

R ISK, ET HICS &CO MPLIA NCE CO MMIT T EE

A P P O I N T M E N T / D I S M I S S A L

R E P O R T I N G I N S T R U C T I O N

D I S C U S S I O N /R E P O RT I N G

E X E C U T I O N - R E L A T E D I N S T R U C T I O N S / S U P E R V I S I O N

I N T E R N A L A U D I T I N G

GENER A L MEET ING O F SHA R EHO LDER S

LEA R N MO R E O N T A KEDA .CO M

BO A R D O FDIR ECT O R S

C H A I RINDEPENDENT DIR ECT O R

A P P O I N T M E N T /D I S M I S S A L /N O N -R E A P P O I N T M E N TO F M E M B E R S

Growth & Emerging Markets Business UnitPresident

U.S. Business Unit & Global Portfolio CommercializationPresident

Japan Pharma Business UnitPresident

Europe & Canada Business UnitPresident

Global Oncology Business UnitPresident

Plasma-Derived TherapiesBusiness Unit President

Global Vaccine Business UnitPresident

Research & DevelopmentPresident

Global Manufacturing & Supply GMS Officer

Global Quality Global Quality Officer

GLO BA L PO R T FO LIO CO MMER CIA LIZA T IO N& R EG IO NA L BUSINESS UNIT S BUSINESS FUNCT IO NS

BUSINESS PA R T NER S

RICARDO MAREK

RAMONA SEQUEIRA MASATO IWASAKI

GILES PLATFORD

TERESA BITETTI JULIE KIM ANDY PLUMP THOMAS WOZNIEWSKI

GERARD (JERRY) GRECO

Global Organization Chart

Global FinanceChief Financial Officer

COSTA SAROUKOS

Global Human Resources Chief Human Resources Officer

PADMA THIRUVENGADAM

Global General Counsel

YOSHIHIRO NAKAGAWA

Global Ethics & Compliance Chief Ethics & Compliance Officer

MWANA LUGOGO

Global Business Development Global Business Development Officer

MARCELLO AGOSTI

Corporate StrategyCorporate StrategyOfficer &Chief of Staff

MILANO FURUTA

GLO BA L SPECIA LT Y BUSINESS UNIT S

Corporate Communications & Public AffairsChief Global Corporate Affairs Officer

SHA R EHO LDER S' MEET ING

BO A R D O F DIR ECT O R S (BO D)A UDIT A ND

SUPER V ISO R YCO MMIT T EE

GRO UP INT ER NA L AUDIT

A SC O FFICE

President & CEO President & Chief Executive Officer

CHRISTOPHE WEBER

NO MINA T IO NCO MMIT T EE

CO MPENSA T IO NCO MMIT T EE

12

TAKAKO OHYABU

Our agile and simple organizaPon empowers local leaders to make decisions and act in the best interests of our paPents.

B

RAJEEV VENKAYYA

High potential talent development moving globally and across business/functions

T A KEDA LEA DER SHIPBEHA V IO R S

A new set of expectations for transformational leadership

Talent Development

LEA DER SHIP A T T A KEDA BR INGS A NEW SET O F EX PECT A T IO NS FO R T R A NSFO R MA T IO NA L LEA DER SHIP

ACCELER ATO R PRO GR A M

International cross-functional development for high-potential employees early in their careers

GLO BA L T A LENT PO O L

Induction training for recently-hired senior leaders

GLO BA L INDUCT IO N FO R UM

Takeda’s executive management team personally nurture talented people to lead the company in the future

PR ESIDENT ’ S FO R UM

ENT ER PR ISE LEA DER S

ACCELER ATO RS

GLO BA L PR O GR A MS

TET

T R A NSFO R MA T IO N LEA DER S

MID-CA R EER FUT UR E LEA DER S

EA R LY CA R EER HIG H-PO T ENT IA LS

T A KEDA EX ECUT IV E T EA M

13

Our employees are the cornerstone of our success.

Our significant investment in training offers everyone the opportunity to work at the highest levels of our industry, with fast-track programs accelera<ng the progress of high-poten<al candidates.

03INNOVATION

How our R&D translate science into highly innovative,

life-changing medicines

Innovation is at the heart of our R&D. Our researchers and scientists are striving to bring scientific breakthroughs from the lab to patients worldwide.

We are a patient-driven, science first R&D organization. We combine our focus on core therapeutic areas with cutting-edge technologies.

15

VACCINESPLASMA-DERIVEDTHERAPIES

ONCOLOGY RARE DISEASES NEUROSCIENCE GASTRO-ENTEROLOGY

Our R&D Focus

Innovative Biopharma

LEARN MORE ABOUT OUR PIPELINE ON TAKEDA.COM

DIVERSIFIED MODALITIES IN RESEARCH

ACTIVE PARTNERSHIPS ROBUST CLINICAL PIPELINE OF NOVEL

MECHANISMS

16

70%

We leverage our own internal research capabilities, while also actively engaging with innovative ecosystems around the world to translate science into highly transformative or curative potential medicines for targeted populations with a high unmet need.

R&D INVESTMENT

$4.5bnPER YEAR

200• Biologics• Cell & Gene

Therapies• Microbiome &

Other Modalities• Peptides &

Oligonucleotides

• Small Molecules

APPROX.

50%Pipeline with orphan drug designation*

Our Internal R&D Engine and External Collaborations

40New molecular en<ty clinical stage assets

APPROX.

Approx.

Approx.

OVER

*31 Orphan Drug Designations in at least one indication for assets in Phase 1 through LCM in 2019 versus 15 in 2018

Our balanced business portfolio which is composed of life-transforming, highly innovative medicines in our key business areas, drives our growth.

17

21%OTHERS

13%NEURO-SCIENCE

13%ONCOLOGY

12%PLASMA-DERIVEDTHERAPY

20%RARE

DISEASES

21%GASTRO-

ENTEROLOGY

PERCENTAGE OF SALES*

5 KEY BUSINESS AREAS

14 STRATEGIC GLOBAL BRANDS

80% OF REVENUE

CORE BUSINESS APPROX.

*Based on Apri l 2019 – March 2020 revenue.

Business Portfolio

04SUSTAINABILITY

Corporate Governance Scorecard

Our long-term commitment along with Sustainable

Development Goals (SDGs)Our employees worldwide decide which activities and partners our Global CSR program supports. Selected employees visit sites supported by those partners through our Employee Participation Program.

Environmental Reduction GoalsAchievements by the end of FY2018

1. Sulfur Oxides (SOX) and Nitrogen Oxides (NOX) resulting from various on-site combustion processes2. Performance against goals excludes contribution from Shire acquisition

19

Takeda is committed to ambitious action to prevent and mitigate the effects of a changing climate and has set a goal of becoming a carbon neutral organization, inclusive of all greenhouse gas emissions throughout our value chain by 2040.

19

GOAL FOR 2020 (BASELINE 2005)

AS OF END FY2018

CO2 25% 33.7%

NOX 20% 59%

SOX 75% 99.1%

FRESH WATER USE 30% 48%

WASTE TO LANDFILL 60% 68.3%JAPAN ONLY

TARGET

LEA R N MO R E A BO UT O UR CO MMIT MENT T O CA R BO N NEUT R A LIT Y O N T A KEDA .CO M

Our Global CSR Program & Partnerships play a vital role in disease prevention and strengthening health care systems through long-term commitments in developing and emerging countries.

Strategic Engagement for Sustainability

Programs selected by employee votes each year

Total amount donated from FY2016-2019

¥10.5Bn

20

GLOBAL CSR PARTNERSHIPS:WORKING TOGETHER WITH GAME-CHANGING MULTILATERAL AND

ACADEMIC INSTITUTIONS WORLDWIDE

LEA R N MO R E A BO UT O UR PR O GR A MS O N T A KEDA .CO M

14Global CSR Programs

GLOBAL CSR PROGRAM ©City Cancer Challenge

©DNDi/Fabio Nascimento

©UNICEF/UN0265456/Chute

Improving Access to Medicines for paKents worldwide

In 2016 we launched a new Access to Medicines strategy focused on geographies and therapeutic areas with high unmet medical needs to tackle the many barriers that prevent patients from accessing the care and treatment they need for complex and rare diseases.Our approach to improving access is sustainable and targeted, to strengthen and transform healthcare systems, at every stage of the patient journey - from awareness and diagnosis, to treatment and ongoing patient support.

Supported more than 125,000 patients with treatment they need

Supported healthcare providers in screening over 1.1 million patients for cancer, hypertension and diabetes

Trained over 4,000 healthcare providers and community health workers to provide improved patient care

Implemented patient-focused access programs in 52 countries and territories

In 2018 the Access to Medicine Index recognized our strategy and the progress we are making in improving access, with Takeda climbing 10 places to rank number five

21LEA R N MO R E A BO UT O UR A CCESS T O MEDICINES ST R A T EG Y O N T A KEDA .CO M

Visit us online atwww.takeda.com

IMPORTANT NOTE This Corporate Overview contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. PANVITAN® and ALINAMIN® are either registered trademarks or trademarks of Takeda Pharmaceutical Company Limited and/or its affiliates in Japan and/or other countries.

TAKEDA GLOBAL HEADQUARTERSCreative Director Kashiwa Sato selected people’s “life force” as the overall concept for the interior design, which is expressed through a series of eight Japanese characters, displayed as instillation art throughout the building.

Published: May 2020Corporate CommunicaSons and Public Affairs